LITHMAX 300 MG — DIN 02266695
LITHIUM CARBONATE : 300 MG · AA PHARMA INC · TABLET (EXTENDED-RELEASE) · wholesale supply in Canada
Health Canada status: MARKETED
What is LITHMAX?
LITHMAX 300 MG contains LITHIUM CARBONATE : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02266695, held by AA PHARMA INC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 14-Jan-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LITHMAX used for?
Treatment of manic episodes of manic-depressive illness. Maintenance therapy to prevent or diminish relapses in bipolar manic-depressive patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Lithium in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
11 holders have a Canadian DIN containing Lithium, across 26 DINs, of which 7 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BAUSCH HEALTH, CANADA INC. | 3 | 2 | CARBOLITH | Sourceable in Canada |
| SEARCHLIGHT PHARMA INC | 2 | 2 | LITHANE | Sourceable in Canada |
| PHARMASCIENCE INC | 4 | 1 | PMS-LITHIUM CARBONATE - CAP 150MG, PMS-LITHIUM CARBONATE - CAP 300MG, PMS-LITHIUM CARBONATE - CAP 600MG, PMS-LITHIUM CITRATE | Sourceable in Canada |
| APOTEX INC | 2 | 1 | APO-LITHIUM CARBONATE | Sourceable in Canada |
| AA PHARMA INC | 1 | 1 | LITHMAX | Sourceable in Canada |
| DOMINION PHARMACAL | 3 | 0 | DOM-LITHIUM CARBONATE | No marketed DIN |
| PALADIN PHARMA INC. | 3 | 0 | PAL-LITHIUM CARBONATE | No marketed DIN |
| PHARMEL INC | 3 | 0 | PHL-LITHIUM CARBONATE | No marketed DIN |
| EURO-PHARM INTERNATIONAL CANADA INC | 2 | 0 | EURO LITHIUM | No marketed DIN |
| LABS MANEY PAUL LABS, DIVISION OF 471449 (ONT) LTEE/LTD. | 2 | 0 | LITHIZINE CAP 150MG, LITHIZINE CAP 300MG | No marketed DIN |
| JANSSEN INC | 1 | 0 | DURALITH TAB 300MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 300 MG |
|---|---|
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route | ORAL |
| Pack configuration (monograph) | Bottles of 100 tablets. |
| Storage | Not explicitly specified in the provided text (standard pharmaceutical storage typically applies, but field remains null if not in text). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Lithium |
|---|---|
| ATC code | N05AN01 |
| AHFS class | 28:28.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02266695 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2266695 |
| Brand name | LITHMAX |
| Generic / active ingredient | LITHIUM CARBONATE : 300 MG |
| Market authorization holder | AA PHARMA INC |
| Health Canada schedule | Prescription |
| ATC code | N05AN01 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N05AN |
| Current status | MARKETED |
| Status date | 14-Jan-2011 |
| Original market date | 2005-04-06 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Acute mania: 1200-1800 mg/day in 2 divided doses. Maintenance: 600-1200 mg/day (usually 900 mg/day). Adjust based on serum levels (0.6-1.2 mmol/L for maintenance). Swallow whole.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Significant brain damage, renal or cardiovascular disease, severe debilitation or dehydration, sodium depletion, patients receiving diuretics, hypersensitivity to lithium or any ingredient.
Warnings and precautions
Lithium toxicity is closely related to serum levels. Monitor renal, thyroid, and cardiac function. Risk of encephalopathic syndrome with haloperidol. May impair driving ability.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
7 of 26 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-LITHIUM CARBONATE | 150 MG | CAPSULE | APOTEX INC | MARKETED | 02242837 |
| CARBOLITH | 150 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | MARKETED | 00461733 |
| CARBOLITH | 600 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | MARKETED | 02011239 |
| LITHANE | 300 MG | CAPSULE | SEARCHLIGHT PHARMA INC | MARKETED | 00406775 |
| LITHANE | 150 MG | CAPSULE | SEARCHLIGHT PHARMA INC | MARKETED | 02013231 |
| PMS-LITHIUM CARBONATE - CAP 150MG | 150 MG | CAPSULE | PHARMASCIENCE INC | MARKETED | 02216132 |
| APO-LITHIUM CARBONATE | 300 MG | CAPSULE | APOTEX INC | DORMANT | 02242838 |
| CARBOLITH | 300 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | DORMANT | 00236683 |
| DOM-LITHIUM CARBONATE | 300 MG | CAPSULE | DOMINION PHARMACAL | CANCELLED PRE MARKET | 02231398 |
| DOM-LITHIUM CARBONATE | 600 MG | CAPSULE | DOMINION PHARMACAL | CANCELLED PRE MARKET | 02231399 |
2 · Same class — other molecules in ATC N05AN
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Lithium | APO-LITHIUM CARBONATE · CARBOLITH · DOM-LITHIUM CARBONATE · DURALITH TAB 300MG · +11 more | 26 | 7 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N05AH | Asenapine · Clozapine · Loxapine · Olanzapine · Quetiapine | 589 | 220 |
| N05AX | Aripiprazole · Brexpiprazole · Cariprazine · Paliperidone · Risperidone | 352 | 175 |
| N05AE | Lurasidone · Ziprasidone | 60 | 41 |
| N05AB | Fluphenazine · Perphenazine · Prochlorperazine · Thioproperazine · Trifluoperazine | 104 | 10 |
| N05AD | Droperidol · Haloperidol | 53 | 9 |
| N05AA | Chlorpromazine · Levomepromazine · Promazine | 51 | 8 |
| N05AF | Flupentixol · Tiotixene · Zuclopenthixol | 25 | 8 |
| N05AC | Mesoridazine · Periciazine · Pipotiazine · Thioridazine | 32 | 3 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is LITHMAX called?
Also recorded in Canada as: lithium carbonate 300 MG Extended Release Oral Tablet [Lithobid] (US), lithium carbonate 300 MG Oral Capsule (US), lithium carbonate 300 MG Oral Tablet (US), lithium carbonate 300 MG Extended Release Oral Tablet (US), lithium carbonate 450 MG Extended Release Oral Tablet (US), lithium carbonate 600 MG Oral Capsule (US), lithium carbonate 250 MG Oral Tablet (US), lithium carbonate 400 MG Extended Release Oral Tablet (US), lithium carbonate 200 MG Extended Release Oral Tablet (US), lithium carbonate 150 MG Oral Capsule (US), LITHIUM CARBONATE (US), LITHIUM CARBONATE ER (US), LITHIUM CARBONATE LITHIUM CARBONATE (US).
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.